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Many cancers, including myeloid leukaemia express the cancer testis antigen (CTA)
DDX43 (HAGE) and/or the oncogene Wilms’ tumour (WT1). Here we demonstrate that
HAGE/WT1-ImmunoBody® vaccines derived T-cells can kill ex-vivo human CML cell lines
expressing these antigens and significantly delay B16/HHDII+/DR1+/HAGE+/WT1+
tumour growth in the HHDII/DR1 mice and prolonged mouse survival in the
prophylactic setting in comparison to non-immunised control mice. We show that
immunisation of HHDII/DR1 mice with HAGE- and WT1-ImmunoBody® DNA vaccines
in a prime-boost regime in two different flanks induce significant IFN-g release by
splenocytes from treated mice, and a significant level of cytotoxicity against tumour
targets expressing HAGE/WT1 in vitro. More importantly, the combined HAGE/WT1
ImmunoBody® vaccine significantly delayed tumour growth in the B16/HHDII+/DR1+/
HAGE+/WT1+ tumour model and prolonged mouse survival in the prophylactic setting in
comparison to non-immunised control mice. Overall, this work demonstrates that
combining both HAGE- and WT1-ImmunoBody® into a single vaccine is better than
either vaccine alone. This combination vaccine could be given to patients whose cancer
expresses HAGE and WT1 in parallel with existing therapies in order to decrease the
chance of disease progression and relapse.
Keywords: WT1, ImmunoBody®, immunotherapy, HAGE, cancer vaccine combination, HHDII/DR1 miceAbbreviations: Allo-SCT, allogeneic-stem cell transplantation; HAGE, helicase antigen; DDX43, DEAD-Box Helicase 43;
WT1, Wilms tumour; CML, chronic myeloid leukaemia; TKIs, tyrosine kinase inhibitors; ER, endoplasmic reticulum; FCS,
Foetal calf serum; b2m, beta2 microglobulin; TAPs, transporter-associated proteins; DMSO, Dimethyl sulfoxide; BFA,
Brefeldin A; RT-qPCR, Real-time quantitative polymerase chain reaction; CT, cycle threshold; MFI, mean fluorescence
intensity; FIR, fluorescence intensity ratio; PI, propidium iodide; FITC, fluorescein isothiocyanate; 51Cr, 51Chromium;
ELISpot, Enzyme-linked immunospot; IVS, in vitro peptide re-stimulation; PD-1, programmed death-1; shRNA, Short
hairpin RNA.
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The role of a cancer vaccine is to stimulate cellular immune
responses that effectively lead to anti-tumour cytotoxic T-
lymphocyte (CTL) responses. We have previously shown that
DNA vaccines in which antigenic epitopes are encoded within an
antibody framework can lead to T cell responses and delayed
tumour growth (1). ImmunoBody(R) vaccines have entered
Phase I clinical trials (2) and demonstrated safety as well as
immune responses in 23/25 evaluable melanoma patients.
Previous studies have incorporated epitopes from a single
antigen to stimulate anti-tumour responses (3) but few have
used epitope combinations that could widen the applicability of
vaccines to stimulate both CD4+ and CD8+ T cell responses and
recognise multiple tumour cell populations (2).
The oncogeneWilm’s Tumour (WT1) has been found to play a
role in normal kidney, genital tract and eye development and be
mutated in someWilms’ tumours. In addition it has been found to
be elevated in uterine leiomyosarcoma and carcinosarcomas (4) as
well as epithelial ovarian cancer (5). However it is frequently used
as a marker of minimal residual disease in chronic myeloid and
acute leukaemia (6) having been found to be overexpressed in
malignant but not healthy haematopoietic cells. WT1 is one of a
number of leukaemia associated antigens that have been
considered as promising targets for immunotherapy because of
their ability to elicit specific immune responses against antigen-
bearing cancerous cells while sparing normal tissues. A National
Cancer Institute pilot project by Cheever et al. (7), developed a
priority-ranked list of cancer vaccine target antigens based on
predefined and weighted criteria for the ‘ideal’ antigen. Although
no single antigen met all of the top subcriteria such as therapeutic
function, immunogenicity and having already been in clinical
trials, WT1 was identified as the top ranked antigen for these
criteria and WT1 is overexpressed in most de novo acute myeloid
leukaemia (AML) cases (8) and in chronic myeloid leukaemia
(CML) (9). More specifically WT1 was shown to be expressed in
50–100% cases of blast crisis but not in chronic or accelerated
phase cases (10).
HAGE is a cancer-testis antigen (CTA), a member of a family
of HAGE was found to be expressed in (12/16) 75% of
carcinomas (11) and in 57% of CML patient samples at
diagnosis (12). Expression of HAGE, like many CTAs (13, 14),
is limited in healthy tissues except immunologically protected
sites such as the testis and placenta, making it an excellent target
for immunotherapy due to its low associated risk of effective
treatment causing damage to healthy tissues.
Leukaemia, and CML in particular, have gained a special
attention in the field of the immunotherapy due to the fact that
the circulating tumour cells are readily accessible to immune attack.
Furthermore, the disease has a well-defined carcinogenesis
pathway that allows for the development of immunotherapies
targeting particular and well characterised targets. CML is a
clonal myeloproliferative disorder resulting from malignant
transformation of the primitive haematopoietic stem cell (HSC).
The disease is characterised by the formation of a fusion gene, called
BCR/ABL1which encodes a chimeric protein that has a constitutive
oncogenic tyrosine kinase (TK) activity. Targeting this enzymeFrontiers in Oncology | www.frontiersin.org 2using tyrosine kinase inhibitors (TKIs) such as imatinib (15), which
is often the first line ‘gold standard’ therapeutic approach, has
significantly improved the clinical outcome for patients with CML.
Despite this, 35-40% of patients with CML on TKIs develop
resistance (16), often due to the clonal outgrowth of CML cells
harbouring BCR-ABL point mutations (recently reviewed in (17).
These findings demonstrate that most TKIs are not curative, but
merely put CML stem cells into a state of autophagy (18). However,
the pathognomonic molecular characteristics of CML and the
particular nature of cancer-host immune cells interaction in
CML, as well as the advantageous immunomodulatory effects of
the imatinib therapy (19), all offer a favourable setting in which
immunotherapeutic strategies could be added with synergistic
effect. Indeed, active immunotherapeutic strategies that enhance
T cell responses against specific antigens in patients on imatinib
therapy could increase the number of patients experiencing relapse-
free survival following cessation of imatinib.
Using data from CML single cell (SC) gene expression
downloaded from GEO database (Acc. No. GSE76312 (20),) we
were able to demonstrate that both HAGE and WT1 genes were
expressed in CML cancer stem cells but not in HSC cells
highlighting the specific tumour cell expression of these
antigens (Supplementary Figure 1). Thus it made sense to
assess the capacity of two sequences, one derived from DDX43
(HAGE) and the other from WT1, to generate effective anti-
tumour immune responses in a humanised HHDRII/DR1 mouse
model and determine the ability the ImmunoBody® DNA
delivery system (1) to induce tumour-specific cell death.
Although ImmunoBody® DNA can be administered via
intradermal, intravenous, intramuscular, subcutaneous or
intraperitoneal routes (21), the standard method is the
intradermal route using a gene gun device in mice, and i.m.
injection combined with electroporation in humans (2). The
overall goal of this study was to evaluate the capacity of a
combined HAGE/WT1 sequence-based vaccine to eliminate/
prevent the growth of HAGE/WT1 expressing tumours. We
hypothesised that combining both HAGE and WT1 vaccines
would be more effective against cancerous cells expressing both
antigens through the reduced chance of escape variants, and also
that such a vaccine could be used against a wider range of cancers
that express either, or both of these antigens.
This study has therefore explored and compared the following
aspects; the immunogenicity of HAGE and WT1 derived
ImmunoBody® vaccines individually and in combination in
HHDII/DR1 mice, the capacity of the vaccines given
individually and in combination to induce activated cytotoxic T
cells that can specifically recognise and kill HAGE/WT1-
expressing targets in vitro, and finally, the in vivo capability of
the combined vaccine to induce tumour rejection using HAGE+/




HHDII-DR1 double transgenic mice expressing human a1 and
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out for the expression of murine MHC class I (H-2b) and II
(I-Ab) were provided by Dr. Lone (CNRS, Orleans, France).
Animal use and care was in accordance with EU Directive 2010/
63/EU and UK Home Office Code of Practice for the housing
and care of animals bred, supplied, or used for scientific
purposes. The studies were undertaken with UK Home Office
approval. Females aged between 6-8 weeks were used for this
study. Three mice per group were used to assess the
immunogenicity of the vaccine in at least two independent
studies, whereas a minimum of 10 mice per group were used
for tumour model experiments.
Cell Lines and Growth Condition
The Transporter-Associated Proteins (TAP) deficient, HLA-A2+
lymphoblastoid suspension cell line, T2 (22), was a gift from Dr.
J. Bartholomew (Paterson Institute, Manchester, UK). The CML
derived cell line K562 was purchased from ATCC, the KCL-22
CML cell line was kindly provided by Anthony Nolan (UK,
https://www.anthonynolan.org). T2 cells, KCL-22 and TCC-S
cells were cultured in the Roswell Park Memorial Institute
(RPMI) 1640 medium (SLS/Lonza, BE12-167F) containing 10%
(v/v) foetal bovine serum (FBS, Life Technologies, 10270106)
and 2mM L-Glutamine (SLS/Lonza, BE17-605E). K562 cells
were cultured in Iscove’s modified Dulbecco’s medium
(IMDM, SLS/Lonza, BE12-722F) containing 10% (v/v) FBS.
For the tumour implant model, the B16F1 (murine
melanoma) cell line was knocked out for both murine
endogenous MHC class I and II by Zinc Finger Nuclease
(ZFN) technology and stably transfected with plasmids
encoding both HHDII and HLA-DR1 molecules. Cells were
grown in RPMI 1640 supplemented with 10% (v/v) FBS, 1% L-
Glutamine, 300mg/mL Hygromycin (Insight Biotechnology,
Middlesex , UK) and 500mg/mL Genet ic in (Insight
Biotechnology). The cells were further transfected with
luciferase and HAGE constructs (23). In this study, the cells
were referred to as hB16/HAGE
+/Luc+, and maintained in
RPMI-1640 medium supplemented with 10% (v/v) FBS, 1% L-
Glutamine, 300mg/mL hygromycin and 550mg/mL zeocin
(Thermo Fisher Scientific, U.K.) to retain luciferase gene
expression, and 1mg/mL puromycin (Thermo Fisher Scientific)
to retain HAGE gene expression. The HEK293T human
embryonic kidney cell line (Thermo Fisher Scientific) was
maintained in DMEM (SLS/Lonza, Yorkshire, U.K.) containing
10% (v/v) FBS and 2mM L-Glutamine - these cells were routinely
used for viral gene transduction. All cells were maintained in a
37°C incubator with 5% (v/v) CO2.
Epitope Prediction
The WT1 protein sequence was screened for peptides that have
binding affinity to HLA-A2 and HLA-DR1 molecules using a
web-based algorithm (www.syfpeithi.de) (24) and peptides
selected according to their binding score. A 15 amino acid long
peptide (VRDLNALLPAVPSLG) derived from the WT1 protein
was chosen. The HAGE 30mer sequence used in this study
(QTGTGKTLCYLMPGFIHLVLQPSLKGQRNR) has
previously been studied by our group (23), and the same classFrontiers in Oncology | www.frontiersin.org 3I and class II HAGE-derived peptides were used herein. All
peptides were synthesised by GenScript Ltd (Piscataway, USA),
with a minimum purity of 80%. All peptides were reconstituted
in 100% (v/v) dimethyl sulfoxide (DMSO) to a stock
concentration of 10mg/mL and stored at -80°C in small
aliquots to minimise the number of freeze/thaw cycles.
Peptide Binding Affinity Assay
A T2 peptide-binding assay was performed to evaluate the binding
affinity of the HAGE and WT1 class I peptide sequences to the
HLA-A2 molecules, as predicted by SYFPEITHI software. T2 cells
are an HLA-A2 human lymphoblast suspension cell line that have
been genetically modified to produce mutated non-functional
TAPs that are necessary to transport MHC class I restricted
peptides into the endoplasmic reticulum (ER). This defect
results in a failure to present internal TAP-dependant peptides
and instead MHC molecules leave the ER and the Golgi
compartments empty, leading to a 70–80% reduction of HLA‐
A2 expression on T2 cell surface. These empty molecules are not
stable and are quickly recycled. However, the empty HLA-A2
molecules on the surface of cells can be stabilised by addition of
exogenous peptides for which they have an affinity (25). T2 cells
are therefore frequently used to validate the binding of
exogenously administered peptides. Briefly, in a sterile 96-well
rounded-bottom plate, T2 cells were plated at 0.5×106 cells/100μL
in serum-free RPMI medium supplemented with 3μg/mL human
b2m (Sigma-Aldrich, Hertfordshire, U.K.) in the presence of
varying concentrations of HAGE and WT1 class I peptides or
with DMSO as negative controls and then incubated at 26°C
overnight. T2 cells were then harvested, washed and stained with
an APC-conjugated human HLA-A2 monoclonal antibody
(BioLegend, 343308, Clone: BB7.2) for 30 minutes at 4°C. Cells
were then washed and stained with propidium iodide (PI, Sigma-
Aldrich) to exclude dead cells, and then immediately run to assess
HLA-A2 expression using a Beckman Coulter Gallios™ flow
cytometer and Kaluza™ data acquisition and analysis software.
Brefeldin A Decay Assay (BFA)
A BFA decay assay was performed to evaluate the stability of the
class I peptide-HLA-A2 complex on the cell surface. For this, T2
cells were seeded in a 96-well rounded-bottom plate at a
concentration of 1×106 cells/100 μL in a serum-free RPMI
medium containing 3μg/mL human b2m. Cells were cultured
with either the candidate peptides at a final concentration of
50μg (as determined by T2 binding assay) or with DMSO as a
negative control and incubated at 26°C overnight. The next day,
one batch of cells was washed and incubated with 10μg/mL BFA
(BioLegend, 420601) for 1 hour at 37°C (Time 0) and thereafter
every two hours until 8 hours. After each incubation, cells were
transferred into 12x75 mm polycarbonate tubes, washed and
stained with an APC-conjugated human HLA-A2 monoclonal
antibody (BioLegend, 343308, Clone: BB7.2) for 30 minutes at 4°
C and analysed using the flow cytometer. Dead cells were
excluded by staining with LIVE/DEAD™ viability dye
(Invitrogen) or PI (Sigma-Aldrich).
The stability of peptide-HLA-A2 complex was assessed by
calculating the DC50 value, which is defined as the time requiredJune 2021 | Volume 11 | Article 636977
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the longer the time for this to happen, the more stable the
complex. The DC50 was calculated according to the formula:
(MFI at a given time point/MFI at time 0) X100%. T2 cells
incubated in the absence of peptide, but in the presence of the
same concentrations of DMSO were used as negative controls.
Target Cell Line Preparation: Gene Knock-
In and Knock Down
The CML derived cell lines, K562, KCL-22 and TCC-S were
genetically engineered to either over express HAGE and/or WT1
proteins or HAGE and/or WT1 expression was silenced. K562
cells constitutively express low levels of HLA and were
electroporated with the pcDNA-3.1/HHDII gene using SF cell
line 4D Nucleofection™ Xkit/Amaxa according to manufacturer’s
instructions. Positively transfected cells were selected using
2000μg/mL of G418. K562/HHDII+ cells and KCL-22 cells were
transduced with HAGE using a PLenti.Puro/HAGE plasmid. An
empty plasmid control PLenti.Puro/empty vector, was used as a
vector control. Cells were selected with 1μg/mL puromycine and
2000μg/mL G418 in a 24-well plate at 37°C in 5% (v/v) CO2. Gene
silencing was performed using short hairpin RNA (shRNA)
sequences targeting the human WT1 (MISSION shRNA/Sigma-
Aldrich in TCC-S cells
(WT1.shRNA1,TRCN0000010466,CGGATGAACTTAGGA
GCCACCTTCTCGAGAAGGTGGCTCCTAAGTTCATC
TTTTTG and WT1.shRNA2, TRCN0000040064,
CCGGGCAGTGACAATTTATACCAAACTCGAG
TTTGGTATAAATTGTCACTGCTTTTTG).
After have being transduced, cells were selected with 1μg/mL
puromycin and assessed for either HAGE or WT1 expression
using Western blot and RT-qPCR.
Real-Time Quantitative Polymerase Chain
Reaction (RT-qPCR)
RT-qPCR was used to assess the expression of the genes of interest
in target cells. Briefly, total RNA was isolated from cell lines using
a RNeasy Mini Kit (Qiagen, Lancashire, UK), following the
manufacturer’s instructions. The quantity and purity of the
produced RNA was evaluated using a NanoDrop™ 8000
Spectrophotometer (ThermoFisher Scientific). 2mg of RNA was
then reverse transcribed into cDNA using Promega M-MLV
Reverse Transcriptase. For each qPCR reaction, 1μL of cDNA
(diluted 1:1 in ddH2O) was mixed with 6.75μL of SYBR™ GreenFrontiers in Oncology | www.frontiersin.org 4Supermix (Bio-Rad, 172-5124), 0.5μL (5pmol) of the forward,
0.5μL (5pmol) of the reverse primer (Sigma-Aldrich) and 3.25μL
of molecular grade water. Each sample was run in triplicate on a
Rotor-Gene Q real-time PCR cycler (Qiagen). Table 1 below
summarises primer pair sequences and annealing temperatures
used in the PCR reaction. It also shows the HAGE-codon
optimised pair primers which were used to detect the
transduced HAGE gene in the modified cells. Expression levels
of each genes were calculated using comparative CT method (27).
Protein Assay and Western Blot Analysis
Immunoblotting was performed to detect HAGE and/or WT1
expression in target cells. Briefly, CML cells were washed twice
with cold DPBS, lysed in bromophenol blue free-Laemmli lysis
buffer containing 0.125M Tris-HCl (pH 6.8), 4% (w/v) SDS, and
20% (v/v) glycerol and 10% (v/v) 2-mercaptoethanol. Cells were
then boiled for 15 minutes at 95°C to denature proteins. To
determine the quantity of protein in the lysates obtained, a
protein assay (Bio-Rad, 500-0116) was performed following the
manufacturer’s protocol, wherein standards were prepared by
serial dilutions of bovine serum albumin (BSA) diluted in
bromophenol blue free-Laemmli lysis buffer. A pre-calculated
volume of sample containing 30μg of protein was loaded onto on
Tris/glycine SDS-polyacrylamide gels alongside 5μL of marker
ladder (Precision Plus Protein™, Bio-Rad, Hertfordshire, UK).
The proteins on gels were then transferred onto Amersham
Hybond-P PVDF membranes (GE Healthcare, Life science, UK)
for 60 minutes at 100V at 4°C. The membranes were then
blocked with TBS-Tween-20 (TBST) containing 5% (w/v)
Marvel milk powder under a constant agitation for 1 hour at
room temperature. After being thoroughly washed, membranes
were blotted with primary antibodies at a concentration
recommended by the manufacturer’s instructions (rabbit anti-
human WT1 antibody, Abcam, Ab89901) and (rabbit anti-
human DDX43 antibody, Sigma-Aldrich, HPA031381) and
kept rocking overnight at 4°C. The next day, the membrane
was washed 5 times with TBST, for 5 minutes each, and
incubated in horseradish peroxidase (HRP)-conjugated
secondary antibodies; HRP-conjugated anti-rabbit IgG
antibody (Cell Signaling Technology, 70745, 1:1000) and HRP-
conjugated anti-mouse IgG (Cell Signaling Technology, 70765).
At the same time, Precision Protein™ Strep-Tactin™ HRP-
conjugate, (Bio-Rad, 161-0380) was also added. Membranes
were kept under a constant agitation for 2 hours at roomTABLE 1 | Primers and annealing temperatures used in RT-qPCR assay.
Primers Sequence Annealing Temp
WT1 forward GACTCATACAGGTGAAAAGC 58°C
WT1 reverse GAGTTTGGTCATGTTTCTCTG 58°C
DDX43 forward CAACACCTATTCAGTCACAG 58°C
DDX43 reverse GACCAGATGAATAAATCCAGG 58°C
GUSB forward ACTGAACAGTCACCGAC 58°C
GUSB reverse AAACATTGTGACTTGGCTAC 58°C
HAGE forward (codon optimised) CCACATGCACTTTCGACGAT 58°C
HAGE reverse (codon optimised) ATTCCTGGTCGGTTCCTCTG 58°CJune 2021 | Volume 11 | Article 636977
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were developed using Clarity™ Western ECL Substrate (Bio-
Rad, 170-5061) and luminescence was detected by G:BOX XT4:
Chemiluminescence and Fluorescence Imaging System
(Syngene). For each sample, mouse anti b-actin was used as a
loading control (Sigma-Aldrich, A5441).
Phenotypic Analysis of Target Cell Lines
Surface staining was performed to characterise target cells
phenotypically to detect HLA-A2 expression using an (APC-
conjugated anti-human HLA-A2 antibody (BioLegend, 343308,
Clone: BB7.2). Phenotypic analysis was also performed to assess
the success of HHDII gene transfection using an FITC-
conjugated anti-human b2m antibody (Sigma-Aldrich,
SAB4700012, Clone: b2M-01). Cells were incubated with PI
immediately prior to running the samples. At the end of the
assay, cells were re-suspended in Beckman Coulter Isoton II™
diluent and analysed immediately on the Beckman Coulter
Gallios™ flow cytometer.
DNA Vaccine-Bullet Preparation
Expression vectors encoding HAGE- and WT1-ImmunoBody®
(28) were coated onto 1.0mm gold microcarriers, as per the
manufacturer’s instructions. In brief, 200mL of 0.05M spermidine
containing 16.6mg of gold was mixed with 36mg of the
ImmunoBody® DNA. After giving the sample a short
sonication, 200mL of 1M CaCl2 was then added in a dropwise
manner to the mixture while vertexing, and then the DNA-gold
complex was kept for 10 minutes at the room temperature. The
pellet was then re-suspended in 2mL of 0.025mg/mL
Polyvinylpyrrolidone after being washed twice with anhydrous
ethanol. After this, and while the tube was sonicating, the sample
was syringed into dried Tefzel™ tubing and kept standing in a
Tubing Prep Station for five minutes. Without disturbing the
gold, the ethanol was then gradually taken off using a syringe.
Nitrogen gas was turned on while the tube was kept spinning for
7-10 minutes inside the station. When completely dried out, the
tube was detached from the station and cut by a guillotine.
Bullets were kept at 4°C until used.
Immunisation Programme
HHDII/DR1 mice were immunised with DNA bullet containing
1μg of either HAGE DNA ImmunoBody® which encodes the
HAGE 30-mer sequence [QTGTGKTLCYLMPGFIH
LVLQPSLKGQRNR] or WT1 ImmunoBody® which encodes the
WT1 15-mer sequence [VRDLNALLPAVPSLG] or both,
administered by gene gun device on Day 1, 7 and 14. On Day 21,
mice were culled and splenocytes were immediately harvested and
used in an IFN-g Enzyme-Linked ImmunoSpot (ELISpot) assay.
Ex Vivo IFN-g ELISpot Assay
The immunogenicity of either HAGE or WT1 peptides was
determined using splenocytes harvested from immunised mice
in an ex vivo IFN-g ELISpot assay (ELISpot kit for mouse IFN-g/
MABTECH, 3321-2A). The assay was performed as previously
described (29). Briefly 0.5x106 of freshly isolated splenocytesFrontiers in Oncology | www.frontiersin.org 5were seeded per well in triplicates into the pre-coated IFN-g
ELISpot plate along with 1mg/mL of either HLA class I or 10mg/
mL of HLA class II HAGE/WT1 derived peptides, cells were then
incubated at 37°C in a 5% (v/v) CO2 incubator for 48 hours. The
plates were then washed and biotinylated detection antibody
against mouse IFN-g was then added and incubated for 2 hours
at room temperature. Plates were then washed followed by the
addition of alkaline phosphatase (AP)-conjugated streptavidin,
after which they were incubated for 60 minutes at room
temperature. Plates were washed, development solution (BCIP/
NBT, Bio-Rad) added left in dark at room temperature until
spots could be seen. Once spots developed, the reaction was
stopped by rinsing the plates under tap water. Plates were then
left to dry and the spots were quantified using an ELISpot plate
reader (Cellular Technology Limited). Staphylococcal
enterotoxin-B (SEB), was used as a positive control, and
unstimulated splenocytes (cells alone) were used as a negative
control for every ELISpot assay. Animals were scored as having a
positive reaction when the number of spots in the cells alone
wells did not reach more than 20 spots and when the response in
the peptide containing wells were at least twice that of standard
deviation of the mean of the control wells.
Chromium (51Cr) Release
Cytotoxicity Assay
Splenocytes derived from vaccinated mice were cultured for 7
days with mitomycin-C treated peptide pulsed LPS blast cells as
previously written (29). Briefly, LPS blast cells were prepared
using splenocytes extracted from naïve mice and stimulated with
LPS and dextran sulphate in a T75 flask. After 48 hours, cells
from LPS blasts were harvested and treated with mitomycin-C.
Following the incubation, cells were washed and counted and
incubated with immunogenic HLA class I peptides, as
determined by the ex vivo IFN-g ELISpot assay for 90 minutes
at 37°C. The peptide-pulsed LPS cells were then washed and co-
cultured with freshly isolated splenocytes from immunised mice
at a ratio (1) LPS (5): splenocytes in the presence of b-
mercaptoethanol and murine IL-2 (mIL-2, Sigma-Aldrich,
I0523, 50U/mL) at 37°C for 6 days. After incubation, LPS
blast/T cells were then harvested, washed and counted to be
ready for co-culture with 51Cr-labelled target cells.
Target cells were labelled with 1.85Mbq of 51Cr in a water
bath at 37°C for one hour. Cells were then washed twice and
rested for another hour at 37°C in 1mL of medium. Meanwhile,
in vitro stimulated T cells were harvested and counted. Effector
cells and target cells were plated in a 96-well rounded-bottom
plate at a final volume of 200μL at different effector: target ratios
of 100:1, 50:1, 25:1 and 12.5:1. Maximum and spontaneous
release were set up in 4 replicates using 1% (w/v) SDS and
plain medium, respectively. After 24 hours of co-culture of the
effector and target cells at 37°C in 5% (v/v) CO2 incubator, 50mL
supernatants were transferred to 96-well Luma plates to be dried
on the plate. The 51Cr release was measured using a TopCount
Microplate scintillation counter (beta scintillation counting) and
the percentage of specific cytotoxicity was calculated using the
following equation:June 2021 | Volume 11 | Article 636977
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=  
(Experimental   release −   Spontaneous   release)
(Maximum   release −   Spontaneous release)
In Vitro Peptide Re-Stimulation (IVS) of the
Murine Splenocytes
Fresh splenocytes isolated from vaccinated animals were
stimulated with either HAGE 30-mer long peptides, WT1 15-
mer long peptides or both, at a concentration of 1mg/mL in the
presence of b-mercaptoethanol and 50U/mL mIL-2 for 7 days at
37°C in a 5% (v/v) CO2 incubator. Cells were then washed and
counted using a NucleoCounter™ (Chemometec).
Tumour Model
In the prophylactic setting, mice were immunised with 1μg of
gold-coated HAGE-ImmunoBody® DNA in one flank and 1μg
of gold-coated WT1-ImmunoBody® DNA into the contralateral
flank simultaneously once, on 3 consecutive weeks (Day-1, -7
and -14). On Day-21, mice received 0.75x106 hB16/HAGE
+/
Luc+. In the therapeutic setting, 0.75x106 hB16/HAGE
+/Luc+
cells were first implanted and the next day mice received the
double vaccine which was then followed by two additional
injections 7- and 14 days post tumour implantation. A control
group of mice received the same dose of tumour cells, but no
vaccines. Animals were monitored twice weekly and tumour
growth assessed by callipers until a palpable tumour was
detected. Mice were then monitored twice weekly by in vivo
imaging until termination. For each imaging session, luciferin
was administered intraperitoneally at 150mg/kg, and anaesthesia
induction began 10 minutes afterwards. All mice were
anaesthetised with an appropriate concentration of isoflurane
and imaged using the IVIS Lumina III system (Perkin Elmer).
Mice were sacrificed when the tumour volume reached a
maximum of 1.2cm2 for the prophylactic group and 1.5 cm2
for the therapeutic group or show clinical signs.
Processing of B16 Tumour Tissue
Tumour Volume and Weight
Once threshold endpoints were reached, tumours were dissected,
weighed and scaled. Tumour volume was measured applying the
formula: P/6 (length X width2). Approximatively 1g of tumour
was excised and enzymatically digested to study tumour-
infiltrating lymphocytes (TILs), the remaining tumour was
snap-frozen in liquid nitrogen.
Isolation of Tumour Infiltrating Lymphocytes (TILs)
Briefly, 1g of tumour tissue was excised from B16 tumours,
chopped into small pieces using scissors and incubated with 5mL
of RPMI containing 1mg/mL of collagenase-I (Sigma-Aldrich,
C0130). The mixture was kept shaking at 37°C for 30 minutes to
help tumour dissociation. Thereafter, the suspensions were
filtered through a 70-mm filter, washed with PBS to remove the
dissociation medium and re-suspended in 5mL of T cell medium.
Cells (1x106) were then stained for CD8 (APC/Cy7™-conjugated
anti-mouse CD8a, BioLegend, 100714, Clone: 53-6.7), CD4Frontiers in Oncology | www.frontiersin.org 6(Alexa-Fluor™ 700-conjugated anti-mouse CD4, BioLegend,
100430, Clone: GK1.5), CD3 (Brilliant Violet™ 421-conjugated
anti-mouse CD3, 100228, Clone: 17A2) and PD-1 (APC-
conjugated anti-mouse CD279 (PD-1), 135210, Clone: 29F.1
A12), as well as ZOMBIE™ or LIVE/DEAD™ Yellow™
viability stains to exclude dead cells. TILs were then analysed
by a flow cytometry.STATISTICAL ANALYSIS
Data were analysed with GraphPad Prism7 software. The Mann-
Whitney U-test was used for comparisons of two non-parametric
datasets and one-way ANOVA or two-way ANOVA tests with
post hoc testing using Tukey’s multiple comparison were used for
multigroup comparisons. For tumour challenge studies, the
survival proportion was evaluated by both the Gehan-Breslow-
Wilcoxon test and the log-rank test. For each test, P-value
(probability value) was calculated, and was found to be
significant if *p-value=<0.05, very significant if **p-
value=<0.01 and highly significant in case ***p-value=<0.001
or ****p-value =<0.0001.RESULTS
Prediction of Peptide Binding to HLA-A2
and HLA-DR1
The immunogenic region of the HAGE antigen was previously
identified in our group using combination approaches of matrix-
screening method of overlapping peptides and reverse immunology.
It has been found that a 30-mer peptide sequence
[QTGTGKTLCYLMPGFIHLVLQPSLKGQRNR]/[position: 286-
316] derived from the HAGE protein is associated with high
immunogenicity, as detected using an ex-vivo IFN-g ELISpot
assay (22). From that sequence, various short peptides were
predicted to bind to HLA class I (HLA-A2) and HLA class II
(HLA-DR1) using the freely available software SYFPEITHI,
Tables 2A, B. Only HLA-A2 and HLA-DR1 restricted peptides
were selected to be used in the HLA-A2/DR1 double transgenic
mice (HHDII/DR1). Similarly, a 15 amino acid HLA-DR1 binding
peptide [VRDLNALLPAVPSLG] derived from the WT1 protein
containing two knownHLA-A2 9-mer (30) was initially assessed for
its binding affinity using the SYFPEITHI database (Tables 2C, D).
In Vitro Peptide-HLA-A*0201 Molecule
Affinity and Stability
Several factors influence the capacity of peptide-MHC
complexes to stimulate T cells, of which the primary two are
the affinity of peptides for the MHC molecules and the cell
surface stability of the peptide-MHC complex (31, 32). Although
scoring of peptide binding to HLA-A2 via the computer
algorithm predictions is useful, its accuracy is less than 70–
80% (33). Therefore, the strength and stability of the interaction
between the respective HAGE and WT1 class I peptides and the
HLA-A2 molecules were assessed experimentally using peptide-June 2021 | Volume 11 | Article 636977
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data in (Figure 1) (A, B) demonstrate that the intensity of HLA-
A2 expression as measured by Mean Fluorescence Intensity
(MFI) progressively increases in a dose-dependent manner in
comparison with the control (MFI produced by cells that were
treated with matched doses of DMSO vehicle control), indicating
a successful peptide-MHC engagement, apart from WT1/P5
which did not increase the MFI, thereby reflecting its poor
binding affinity toward HLA-A2 molecules. In addition, the
Fluorescence Intensity Ratio (FIR) was calculated for each
peptide concentration using the MFI of HLA-A2 expressed by
T2 cells incubated with peptides and the MFI of HLA-A2
expressed by T2 cells that were incubated in the absence of
peptide, but with the same concentrations of DMSO as
background level of HLA-A2 molecules present on the surface
of T2 cells. A summary of the results is shown in Table 3.
Peptides with FIR=1 were categorised as being non-binders,
1<FIR ≤ 1.5 as weak binders, 1.5<FIR<2 as moderate binders and
2≤FIR as strong binders. All HAGE peptides demonstrated
strong binding affinity towards HLA-A2 molecules, from
30mg/mL onwards (Figure 1A and Table 3). WT1 peptide, P3,
was found to be a strong binder even at 10mg/mL, whereas WT1/
P5 exhibited the least binding affinity with a score of 1 (non-
binder) at 10 μg/mL, and only weak binding capability (1.4 to
1.5) at the higher concentrations (Figure 1B and Table 3).
The persistence of the peptide-HLA class I complex on the
cell surface was assessed in a time course manner using a
Brefeldin A (BFA) assay (Figures 1C, D). BFA has a trap effect
by obstructing anterograde transport of vesicles from the ER to
the Golgi apparatus, thereby preventing peptide-MHC proteins
from being transported to the cell surface. Results in Figures 1C
show that there is a steady, time-dependent reduction in the
level of MFI in all complexes within the first hours of study, but
that the reduction stopped after 6 hours. With regards of the
DC50 value, all HAGE and WT1/P3-HLA-A2 complexes on the
T2 cell surface were stable as their DC50 values were all moreFrontiers in Oncology | www.frontiersin.org 7than 8 hours (Figure 1D). However, WT1/P5-HLA-A2
complex exhibited a poor stability, as DC50 value fell before
6 hours.
Immunogenicity of HAGE- and WT1-
ImmunoBody® Vaccines
To determine the immunogenicity of the HAGE (30mer) and
WT1 (15mer) sequences and whether the predicted HLA-A2 and
HLA-DR1 derived from these sequences were endogenously
processed, HHDII/DR1 mice were immunised with either
HAGE-ImmunoBody® or WT1-ImmunoBody® constructs on
Day- 0, -7 and -14 (Figure 2A). On Day 21, animals were culled,
and their respective spleens harvested and assessed in an ex-vivo
IFNg ELISpot assay. Results in Figure 2B confirms the
immunogenicity of two class I peptides (HAGE/P5 and
HAGE/P6) and one class II (HAGE/P7) in comparison to cell
alone (cells that did not receive any peptide) as reflected by the
high number of IFN-g producing cells (P-value<0.0001, n=3).
Whereas, HAGE/P4 and HAGE/P8 peptides did not produce any
IFN-g, indicating that these peptides were not endogenously
produced and presented to T cells in vivo. WT1-specific
responses induced by a novel WT1 DNA ImmunoBody®
vaccine was also assessed and the results in Figure 2C
demonstrate the immunogenicity of WT1/P1 and WT1/P3,
and the poor immunogenicity of WT1/P5.
In Vitro Recognition and Killing of CML
Targets Expressing HLA-A2, HAGE and
WT1 Antigens by Dual Vaccine-Induced
T Cells
K562, KCL-22 and TCC-S CML cell line-derived targets were
assessed for HLA-A2 expression. Histograms in Figure 3B shows
that that only a small percentage of K562 cells naturally express
HLA-A2, whereas a high percentage of KCL-22 and TCC-S cells
are HLA-A2 positive (Figures 3A, B). Therefore, K562 cells wereTABLE 2 | Class I and class II peptides sequence derived from the entire length of the HAGE and WT1 proteins.The entire HAGE protein sequence of 648 amino acid length, from which the long 30-mer (yellow highlighted in A) and other short 9-15-mer peptides derived from the long 30-mer are
shown in A&B. This length was fully copied from NCBI website/FASTA, available at: https://www.ncbi.nlm.nih.gov/protein/Q9NXZ2.2?report=fasta. Whereas the entire WT1 protein
sequence of 522 amino acid length (Isoform-D), from which the long 15-mer (yellow highlighted in C) and the two others short peptide derivatives are illustrated in C&D. This length was fully
copied from NCBI website/FASTA available at: https://www.ncbi.nlm.nih.gov/protein/NP_077744.4?report=fasta.June 2021 | Volume 11 | Article 636977
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chimeric HLA-A2 gene (HHDII). Figure 3C demonstrates the
success of HHDII transfection of K562 cells.
The constitutive expression at mRNA and protein levels of
both HAGE and WT1 was then determined in all CML targets
using RT-qPCR and Western blotting (Figures 3D, E). All cell
lines expressedWT1mRNA and protein, whereas HAGEmRNA
and protein expression was only detected in TCC-S cells.
Therefore, both K562/HHDII+ and KCL-22 cells were then
transduced with PLenti-Puro/HAGE plasmid construct,
followed by antibiotic selection using puromycin to maintain
HAGE expression in addition to G418, for K562/HHDII, to
maintain HHDII gene expression. Post selection, the success ofFrontiers in Oncology | www.frontiersin.org 8the transduction was demonstrated at mRNA and protein levels
using RT-qPCR and Western blot (Figures 3F, G).
TCC-S cells were found to express HLA-A2, WT1 and HAGE
proteins. It was expected that knockdown of WT1 in these cells
could establish a negative control for WT1 expressing TCC-S
(wild-type) upon assessing the responsiveness of WT1-specific
CTLs in the cytotoxicity assay. Data in Figure 3H demonstrate
the outcome of WT1 knockdown in TCC-S at protein level using
two WT1.shRNA sequences in comparison with cells that were
transfected with the lentiviral carrying the empty vector
(PLKO.1.Puro), as a control vector. Although both sequences
of shRNA were successful in significantly inhibitingWT1 protein
expression, theWT1.shRNA.1 appeared to be more efficient thanTABLE 3 | Categorisation of the binding affinity of class I HAGE- and WT1-derived peptides toward HLA-A2 molecules, as assessed using the T2 binding assay.
Peptides FIR obtained from various HAGE and WT1 peptide doses
10µg/mL 30µg/mL 50µg/mL 100µg/mL
HAGE/P4 1.8 (moderate) 2.3 (strong) 2.4 (strong) 2.3 (strong)
HAGE/P5 1.9 (moderate) 2.4 (strong) 2.4 (strong) 2.3 (strong)
HAGE/P6 1.8 (moderate) 2.3 (strong) 2.3 (strong) 2.2 (strong)
WT1/P3 2.6 (strong) 3.3 (very strong) 3.4 (very strong) 3.5 (very strong)
WT1/P5 1.0 (non) 1.4 (weak) 1.4 (weak) 1.5 (weak)June 2021 | Volume 11Serial doses were used to assess peptides binding affinity toward HLA-A using flow cytometry, peptides were then categorised for being a strong, moderate, and weak HLA-A2 binder
according to Fluorescence Intensity Ratio (FIR).A
B D
C
FIGURE 1 | In vitro determination of the HAGE and WT1 peptides-HLA-A*0201 molecule affinity and stability. The affinity of class I HAGE peptides (HAGE/P4,
HAGE/P5 and HAGE/P6) shown in (A) and WT1 peptides (WT1/P3 and WT/P5) shown in (B) to bind HLA-A2 molecules in comparison to controls (DMSO-treated
cells) was determined using the T2 binding assay. T2 cells were incubated with 10, 30, 50 and 100µg/mL peptide in serum-free media containing 3µg/mL human
b2m overnight in a 26°C incubator. Cells were stained with an anti-HLA-A2 antibody and propidium iodide (PI), and then immediately analysed using a flow
cytometer. Values are expressed as the mean ± SD of three independent experiments and the level of significance was determined using Two Way ANOVA, followed
by Tukey’s multiple comparisons test. Results indicate that all peptides were strong binders to MHC class I with the exception of WT1/P5. The binding stability
(measured by MFI) of class I HAGE peptides and WT1 peptides shown in (C) in comparison to cells that were incubated with the same concentration of DMSO.
DC50 for these peptides is shown in (D). T2 cells in serum-free medium containing human b2m at 3µg/mL were incubated with 50µg/mL of the respective peptides
overnight and assessed in a time course analysis for HLA-A2 expression using a flow cytometer. Values are expressed as the mean ± SD of two independent
experiments. All peptide-HLA complexes studied are stable on the T2 cells surface as their DC50 values were > 8 hours, apart from the WT1/P5- HLA-A2 complex
which shows poor stability as there was a drop in DC50 value earlier between 5-6 hours. *p-value=<0.05, significant; **p-value=<0.01, very significant and ****p-
value=<0.0001, highly significant, ns, not significant.| Article 636977
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FIGURE 2 | Immunogenicity of HAGE- and WT1-ImmunoBody® vaccines, as determined using the IFN-g ELISpot assay. Schematic presentation of ImmunoBody®
immunisation regime is demonstrated in (A) where a prime-boost strategy was applied to assess the immunogenicity of HAGE-and WT1- ImmunoBody®
administered in separate sets of mice. In this programme, each mouse received a total of three injections at 7-day intervals and spleens were then harvested on Day-
21 for IFN-g ELISpot assay. The level of IFN-g produced by fresh 0.5x106 splenocytes harvested from a group of mice immunised and boosted with HAGE-
ImmunoBody® (B) and WT1- ImmunoBody® vaccine (C) were assessed using the ELISpot assay. Values are expressed as the mean ± SD of at least 8 independent
experiments (3 mice/group) and the level of significance was assessed using One Way ANOVA followed by Dunnett’s multiple comparisons test. Results in (B)
demonstrate the potent immunogenicity of the two class I peptides; HAGE/P5 and HAGE/P6 and one class II; HAGE/P7 in comparison to cells alone, whereas the
class I HAGE/P4 and class II HAGE/P8 are shown to be poorly immunogenic. Results in (C) demonstrate the potent immunogenicity of WT1/P3, mild









FIGURE 3 | HLA-A2, HAGE and WT1 expression in target cells: (A) Representative gating strategy used for the analysis of the surface expression of HLA-A2 on
targets, as assessed by flow cytometry. Live cells were first gated according to their Side Scatter and Forward Scatter profile, and then single cells were selected,
avoiding doublets. (B) The level of surface HLA-A2 expression was determined on basis of fluorescence intensity depicted by a shift to the right of the histogram in
comparison to unstained samples. (C) Overlay histogram illustrates HLA-A2 surface expression on the targets in comparison to a negative control (non-stained
sample). The constitutive expression of WT1 and HAGE by KCL-22, K562 and TCC-S cell lines using RT-qPCR and Western blot shown in (D, E). HAGE is
transcribed at low levels in KCL-22 and K562 cells, but protein level are high. In contrast, TCC-S cells have constitutively high HAGE transcript and protein levels.
WT1 was expressed by all cells studied as detectable by transcription and and protein levels. The Success of transfection; knock-in and knockdown, seen in (F–H)
Values of PCR are expressed as the mean ± SD of two independent experiments. The doublet on WT1 seen in the Western blot might represent WT1 isoforms
resulting from an alternative splicing event. ****p-value=<0.0001, highly significant.Frontiers in Oncology | www.frontiersin.org June 2021 | Volume 11 | Article 6369779
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used in the cytotoxicity assay. All the modified cell types
were periodically checked for the maintenance of the
transduced genes.
Once all the target cells had successfully been “engineered” to
express the correct HLA-A haplotype and/or antigens the ability
of the vaccine induced cells to recognised and kill them was
assessed. Briefly, splenocytes harvested from animals immunised
with either HAGE-ImmunoBody® alone, WT1-Immunobody®
alone or both were co-cultured in vitro with mitomycin-C treated
and peptide-pulsed LPS blasts at ratio of 1:5 (LPS blast: T cell) for
6 days. Cells were then plated with 51Cr labelled K562 cells at
various target: effector ratios (1:100, 1:50, 1:25, and 1:12.5) for 24
hours at 37°C. Supernatants were then transferred onto Luma
plates and read using a TopCount beta scintillation counter.
Figure 4 shows that in vitro expanded cells from all
vaccinated mice were able to specifically recognise and kill all
the target cells expressing the antigen against which the mice
were vaccinated, Figure 4 (A1, A2) (B1, B2) (C1, C2). Moreover,
cells derived from the mice immunised with both HAGE-
and WT1-ImmunoBody® vaccines could consistently kill
significantly more target cells expressing both antigens
indicative of a synergistic effect achieved with the combined
vaccines Figure 4 (A3, A4) (B3, B4) (C3, C4) (P-value<0.0001,
n=3) in almost all ratios used.
In our previous studies, the B16/murine MHC knockout/
HHDII+/DR1+ murine melanoma cell line was shown toFrontiers in Oncology | www.frontiersin.org 10constitutively express the murine WT1 protein (data not
shown). Herein, these cells (with/without HAGE) were used as
targets to assess the capability of HAGE- and WT1-
ImmunoBody® vaccines derived cells to provoke in vitro
killing activity. Figure 4D highlights the significant difference
in the lysis produced by each indicated group against these cells.
Here again, a statistically significant difference was found
between the killing of B16 cells expressing HAGE (almost
50%) and HAGE-negative B16 (20%) at 1:100 ratio (shown in
D1), whereas no differences in killing were found against these
two targets when the effector cells used were derived from mice
immunised with only WT1 (shown in D2), since both express
murine WT1. This indicates that the WT1 peptide used in this
study was endogenously processed naturally and presented on
the surface of the B16 cells and was recognised by cytotoxic T
lymphocytes (CTLs). Again, as for the other targets, a
significantly higher percentage of B16/HAGE+ cells was killed
when the CTLs used were derived frommice immunised with the
combined approach (Figure 4D, at almost 60%) than when they
were derived from mice immunised with either HAGE or WT1
vaccine individually (50% and 45%, respectively). This difference
is shown to be a statistically significance at 1:100 (target: effector
ratio) (P-value=0.0032, n=3 and P-value=0.0002, n=3) in HAGE
and WT1 groups, respectively.
Overall, these findings demonstrate that the sequences
contain within HAGE- and WT1-ImmunoBody® derived
vaccines either individually or in combination wasA1 A2 A3 A4
B1 B2 B3 B4
C1 C2 C3 C4
D1 D2 D3 D4
FIGURE 4 | Specific in vitro killing of target cells by vaccine induced CTLs, as assessed by 51Cr release assay. Splenocytes from mice immunised with HAGE, WT1
and combined, were co-cultured in vitro with mitomycin-C treated and peptide-pulsed LPS T cells for 6 days and then plated with 51Cr labelled-targets at various
ratios for 24 hours at 37°C, followed by measuring 51Cr in the medium. Values are expressed as the mean ± SD of three independent experiments (3 mice/group)
and the level of differences between groups were assessed using Two Way ANOVA followed by Tukey’s multiple comparisons test. Results demonstrate that the
percentage of lysis generated from combined vaccine is higher than the individual vaccines. P*-value < 0.05, **p-value < 0.01, ***p-value < 0.001, ****P-value <
0.0001 versus the corresponding control group. NS, not significant.June 2021 | Volume 11 | Article 636977
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presenting cells (APCs) in association with HLA-A2 molecules
leading to the development of professional CTLs which are able
of specifically recognising and killing antigen-expressing target
cells. They also indicate that the combination approach improves
CTL responses.Efficacy of the Combined HAGE/WT1
ImmunoBody® Vaccines in HHDII/DR1
Mice Bearing the Aggressive hB16/HAGE
+/
Luc+ Tumour
The efficacy of the combined HAGE/WT1 ImmunoBody®
vaccines was then tested in both prophylactic and therapeutic
settings in female HHDII/DR1 mice (n=10/group) using the
aggressive hB16/HAGE
+/Luc+ tumour. In the prophylactic
setting, mice were first immunised with both HAGE- and
WT1-ImmunoBody® vaccines 3 times, a week apart, and on
Day 21 mice were then challenged with subcutaneous injection of
hB16/HAGE
+/Luc+ cells, as shown in Figure 5A1. In the
therapeutic setting, mice were first implanted with the sameFrontiers in Oncology | www.frontiersin.org 11dose of hB16/HAGE
+/Luc+ cells, followed by immunisation the
next day, and then received two more injections of the dual
HAGE/WT1 ImmunoBody® vaccines 7 days apart. The control
group received no vaccine (Figures 5A2, A3).
Details of bioluminescence images and mice culling per
session are shown in Supplementary Figure 2. Mice that did
not receive the vaccines had to be sacrificed as early as Day 39
post-implantation due to tumour size endpoints, whereas
tumour growth was delayed in mice that combined vaccines in
comparison to the controls (Figure 5). Indeed, at around day-46
post-implantation, the number of surviving mice was 8/10 (80%)
for the prophylactic group and 6/10 (60%) for the therapeutic
group, in comparison with only 1/10 (10%) for the control group.
Tumour growth, as measure by the total luminescence flux for
each group was recorded and plotted in Figure 5B. Eventually, 4
mice from prophylactic group (Mouse-6, Mouse-7, Mouse-9 and
Mouse-10) and one mouse from the therapeutic group (Mouse-
24) were the last mice to be culled. The study was then
terminated on Day 56 post-implantation before the tumours
reached their end point size. This was purposely done in order to





FIGURE 5 | Combined HAGE/WT1 ImmunoBody® vaccines significantly delay tumour growth in tumour challenge experiment. Schematic representation of the in
vivo experimental design is shown in (A) where three groups of mice were used in this study using prime- boost regime. In the prophylactic setting, mice were
received the vaccine then challenged with hB16/HAGE+/Luc+ cells on Day-21, whereas, in the therapeutic setting, tumour cells were implanted, followed by
vaccination in the determined days. The control group of mice received DPBS instead of the vaccine. Intra-tumoural luciferin bioluminescent signals in the vaccinated
HHDII/DR1 mice bearing the aggressive hB16/HAGE+/Luc+ tumour in comparison to the control are shown in (B). The figure demonstrates the prophylactic and
therapeutic efficacy of the combined HAGE/WT1 ImmunoBody® vaccines, wherein luciferin bioluminescent signals were detected in all groups as a total flux
measured by photons/second. Data shows that the total flux in the prophylactic group and therapeutic declined in comparison with the control, and that both
treatment settings led to prolong mice survival rate. Most mice from the control group were culled after Day-39 post transplantation session whereas mice in the
vaccinated groups survive while they were holding small size tumour. Post-culled hB16/HAGE+/Luc+ tumour weight and volume are shown in (C, D). For each
indicated group, tumour weight in grams and tumour volume in mm3 were determined, and post-culled tumour images highlighted the tumour size shown in (D).
Mice were euthanized when tumour size reached endpoint threshold (12 mm2 for the prophylactic setting and 15 mm2 for the therapeutic setting). (E) Data in these
graphs are expressed as the mean ± SD, and the level of the significance was determined using one-way ANOVA analysis followed by Dunnett’s multiple
comparisons test. Survival analysis demonstrates the antitumor efficacy of the combined HAGE/WT1 ImmunoBody® vaccines in vaccinated tumour bearing mice.
Results shows that the combined HAGE/WT1 vaccines is significantly protective in the prophylactic group in comparison to the control group at **P-value<0.01, but
not in the therapeutic setting. The significance of the difference was evaluated by both Gehan-Breslow-Wilcoxon test and log-rank test. The total number of mice is
30, (10/group). *p-value=<0.05, significant; **p-value=<0.01, very significant, ns, not significant.June 2021 | Volume 11 | Article 636977
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performed functional assay on splenocytes extracted from
these mice.
Interestingly, although the total luminescence flux signals, as
expected, were very similar on Day 22 (one day post-transplant),
10 days later, a statistically difference between the size of the
tumours for the prophylactic group and those for the control was
detected. Thereafter, the size of the tumour in the prophylactic
group and for the therapeutic group remained below the 1x109
threshold for the majority of the tumours. However, by Day 39,
tumours in a distinct group consisting of 4 mice separated from
the rest of the prophylactic group, continued to grow until they
had to be culled on Day 46. In the future, it would be important
to re-immunise animals showing such a trend before their
tumour became too large. It is also evident from the data that
for 7 out of the 10 mice that received the vaccine after tumour
implantation, the tumour first regressed below the 1x109
threshold, whereas the size of the tumours from the control
group was, for the majority, above or very near this value (with
the exception of one mouse), but then by Day-39 these increased
again. This demonstrates the ability of the combined vaccines to
delay the growth of the tumour, but there would likely be a
requirement for further vaccination on Day-39 or additional
interventions, such as checkpoint inhibitor. The survival
proportion in Figure 5C clearly demonstrates that the
combined HAGE/WT1 ImmunoBody® vaccines were able to
significantly delay the aggressive growth of B16 melanoma cells
and increases the overall survival in the prophylactic setting in
comparison to the control at **P-value<0.01. However, this level
of efficacy was not shown in the therapeutic group.
Tumour volume and weight were measured as soon as
animals were culled. Data in Figure 5D demonstrates that
there was a significance difference in the tumour volume in the
prophylactic and therapeutic group compared to the control
(P-value =0.003, n=10 and P-value= 0.0271, n=10), respectively,
which indicates a shrinkage of the tumour, probably due to the
activation of anti-B16 CTLs.
The Combined HAGE/WT1 ImmunoBody®
Vaccine Provokes In Vivo Anti-Tumour
Effector T Cell Function in HHDII/DR1
Mice Bearing hB16/HAGE
+/Luc+ Tumour
Until Day 56 post-implantation, all mice were sacrificed due to
tumour size reaching the endpoint threshold, except for Mouse-
6, Mouse-7, Mouse-9 andMouse-10 from the prophylactic group
and Mouse-24 from the therapeutic group. However, it was
decided to terminate the study to enable the analysis of TILs
and perform functional assays, such as IFN-g ELISpot.
The immune response generated in these mice was compared
with that of the IFN-g response assessed in a set of mice culled
earlier in the study, (Mouse-11, Mouse-13, Mouse-15 and
Mouse-16) from the control group and one mouse from the
therapeutic group (Mouse-22). Interestingly, comparing data in
Figure 6A1 versus A2, IFN-g production was significantly
greater in the surviving mice than those which were culled
early in the study due to their tumour size reaching the endFrontiers in Oncology | www.frontiersin.org 12point. Vaccinated mice which had to be sacrificed early in the
study due to tumour size (such as mouse-22) lacked the
development of a specific anti-tumour immune response and
therefore could not maintain tumour growth in a similar pattern
as the control. IFN-g production from spleens of these mice was
also assessed after 1week in vitro stimulation (IVS) using the
IFN-g ELISpot assay. As demonstrated in Figure 6A3, IFN-g
secretion was significantly increased after IVS in comparison
with those obtained straight ex-vivo demonstrating that these
cells can be further expanded in vitro after in vivo priming.
Phenotypical Characterisation of T Cells
and TILs From Mice Bearing hB16/HAGE
+/
Luc+ Tumour
The profile of tumour-infiltrating lymphocytes (TILs) was assessed
and compared with T cells extracted from spleens from tumour
bearing mice. After each culling, a small piece of tissue was
immediately digested and stained with anti-mouse CD3, CD4,
CD8a and CD279 PD-1 antibodies. Thereafter, samples were
assessed by flow cytometry and analysed according to the gating
strategy shown Figure 6B. Figures 6C, D demonstrates the
expression pattern of CD3+, CD4+, CD8+ and PD-1 on TILs and
T cells from freshly isolated splenocytes from tumour bearing mice
in both treatment settings in comparison to the control group. From
these data, the following points can be concluded; firstly, the
majority of CD3+ T cells recruited in spleens were CD4+ cells,
whereas the majority of CD3+ T cells in all tumours studied were
CD8+ cells, indicating a reversal in the CD4+/CD8+ ratio of TILs in
comparison with those derived from the spleens. Although this
trend was observed regardless of whether the mice were vaccinated,
the percentage of CD8+ T cells within the tumour of the
prophylactic and therapeutic mice was significantly higher than
the control at ***P-value= 0.0003 and *P-value= 0.0323, respectively,
indicating that the combined vaccines were able to recruit more
CD8+ cells in the vaccinated group in both the prophylactic and
therapeutic settings. Secondly, more than 60% of CD4+ and CD8+
TILs expressed PD-1 compared to 5-10% in the spleens, suggesting
that T cells of both types CD4+ and CD8+ in the tumour
microenvironment have been jeopardised by immunosuppressive
elements, PD-1, which might be induced by immune
immunosuppressive cells in the hostile B16 microenvironment.
Finally, the percentage of CD4+PD-1+ cells in the tumour was
higher in the prophylactic group at **P-value= 0.0046 than
the control.DISCUSSION
Although the choice of antigen and peptide sequence remain crucial
elements for the success of peptide-based vaccines, the adjuvant
and/or delivery system and route of delivery used with these also
play an important role in the intensity and duration of the response.
It is now well established that long peptide vaccines are preferred to
single CD8 epitopes due to their capacity to harbour multiple CD8+
and CD4+ T cell epitopes and bind to a wider range of HLA-
haplotypes, thereby increasing their efficiency at generating durableJune 2021 | Volume 11 | Article 636977
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multiple antigens, and epitopes therein, reduces the risk of escape
variants. HAGE and WT1, have both been shown to be
immunogenic (36, 37), with the HAGE long 30-mer peptide
sequence [QTGTGKTLCYLMPGFIHLVLQPSLKGQRNR] having
been found to be immunogenic and to encompass several
immunogenic class I and class II restricted epitopes that bind to
HLA-A2 and HLA-DR1 haplotypes (23). The superiority of
ImmunoBody® over peptide immunisation has previously been
demonstrated using several different antigens including HAGE (23,
28). Hence, the present study focused on the use of two
ImmunoBody® vaccines - HAGE-ImmunoBody® and WT1-
ImmunoBody® vaccine. In a similar manner, a 15 amino acid
peptide [VRDLNALLPAVPSLG] derived from the WT1 protein
contained two known and previously published HLA-A2 9-mers,
and was selected so the efficacy of the WT1 vaccine could be
studied. Here the combination of both HAGE and WT1 HLA-A2
restricted epitopes were evaluated for their MHC binding affinity in
vitro using a T2 binding assay. Results showed that all HAGE HLA-Frontiers in Oncology | www.frontiersin.org 13A2 restricted peptides; HAGE/P4, HAGE/P5, and HAGE/P6 were
able to stabilise HLA-A2, as was reflected by the high FIRs which
correlated with the SYFPEITHI software predication of high
binders. Likewise, the binding affinity of WT1 peptides to HLA-
A2 was experimentally studied. WT1/P3 was found to be a very
strong HLA-A2 binder, which would reasonably be expected to
activate WT-1 specific T cells in vitro and in vivo. On the other
hand, although WT1/P5 has a predicted SYFPEITHI score of 27, it
exhibited low binding capability to HLA-A2 which was not
improved with higher peptides concentrations. It was therefore
categorised as being a weak HLA-A2 binder. However, while a high
peptide binding affinity to MHC is associated with high frequency
peptide-MHC complex production, it does not necessarily mean
that these complexes will induce potent T cell activation, as in some
instances peptide-MHC complexes are relatively unstable and
subject to rapid recycling and endocytosis, thereby hindering T
cell recognition and subsequent killing. In addition, it has been
reported that the peptide-MHC stability, more than the peptide-
MHC binding affinity, is linked to T cell activation (38). It wasA1 A2 A3
B
DC
FIGURE 6 | Number of IFN-gamma symbol producing cells can be further expanded in vitro. Tumour induced PD-1 expression on T-cells. Ex vivo IFN-gamma
symbol ELISpot analysis on splenocytes derived from HHDII/DR1 tumour bearing mice vaccinated by the combined HAGE/WT1 ImmunoBody® vaccines shown in
(A). Result of direct ELISpot assay on fresh splenocytes derived from the last surviving tumour-bearing mice from the prophylactic group (Mouse-6 ,Mouse-7 ,
Mouse-9 and Mouse-10) and one mice from therapeutic group (Mouse-24) shown in (A1) versus samples from mice culled earlier shown in (A2), cells were
harvested and plated at a density of 0.5x106 cells/well and re-stimulated with 1µg/mL of short peptides for 48hours. Results demonstrate that IFN-gamma symbol is
much greater in the surviving mice than the control. These splenocytes were also assessed in vitro after one-week stimulation using IVS assay, wherein, cells were
incubated at a density of 0.1x106 cells/well with 1ug/mL short peptides shown in (A3). Results reveal that there was a significance induction of IFN-gamm symbol
secretion after 1-week IVS. Data plotted as an average of spots/mouse, expressed as the mean ± SD of all 5 mice and the level of the significance was assessed
using two-way ANOVA. Cells were processed and incubated with anti-mouse FcR block at 1mg/test for 15 minutes at 4°C and then stained with surface antibody;
anti-CD3, -CD4, -CD8, -PD-1 and LIVE/DEAD YellowTM stain for 30 minutes at 4°C, cells were then assessed by a flow cytometry. Overall profile of T cells derived
from spleens and TILs harvested from vaccinated and non-vaccinated tumour-bearing mice were analysed according to the gating strategy shown in (B) and the
results are presented in (C) (for the % of T-cells) and (D) (for the % of PD1+). Data are expressed as the means± SD of at around 10 mice/group and the level of
significance were assessed by two-way ANOVA followed by Dunnett’s multiple comparisons test. Data demonstrate an inversed CD4:CD8 ratio derived from tumour
in comparison to spleens and demonstrates PD-1 upregulation in the T cells derived from tumour tissues. *p-value=<0.05, significant; **p-value=<0.01, very
significant; ***p-value=<0.001 and ****p-value=<0.0001, highly significant, ns, not significantJune 2021 | Volume 11 | Article 636977
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MHC complex on T2 cells using DC50 as an indicator (the time
required for a 50% reduction in the MFI), such that the higher the
DC50 the more stable is the interaction between peptide and MHC.
This study revealed that all HAGE-HLA andWT1-HLA complexes
were associated with rapid dissociation within the first 6 hours of
the experiment, as reflected by the drop in the MFI values, however
this decline seemed to stop thereafter. As far as the DC50 value is
concerned, the results indicated that all complexes were technically
stable, as there was less than 50% reduction in MFI in comparison
to time zero during the time range of the experiment (>8 hours),
except for WT1/P5-HLA-A2 complex which showed poor stability
as its DC50 value was between 5-6 hours. Collectively, the feasibility
of using the candidate peptides for future experiments was
validated, as they were associated with strong binding affinity
toward HLA molecules as well as potential resistance to the
dissociation, except for WT1/P5 which demonstrated low binding
and early dissociation from HLA-A2 molecules.
The endogenous presentation of these peptide after
vaccination of HHDII/DR1 mice with HAGE-ImmunoBody®
and WT1-ImmunoBody® were then assessed using direct ex
vivo IFN-g ELISpot in order to determine the frequency of T cell
responses. Class I HAGE/P5, HAGE/P6 and class II HAGE/P7
epitopes were all associated with high T cell responses. However,
no specific IFN-g response was detected for the class I peptide
HAGE/P4, indicating this peptide may not be endogenously
processed, despite being a strong and stable HLA-A2 binder.
WT1/P3 epitope was found to elicit high number of IFN-g
producing cells in response to WT1-ImmunoBody®
vaccination while WT1/P5 peptide was not recognised by the
vaccine-induced splenocytes as indicated by a lack of IFN-
g production.
The capability of HAGE/WT1-ImmunoBody® induced T
cells to recognise and kill HAGE and WT1 expressing
leukaemia cells was then assessed using in vitro cytotoxicity
assays. For this purpose, three CML cell lines were chosen, K562,
KCL-22 and TCC-S cells. TCC-S and KCL-22 cells were found to
express HLA-A2, unlike K562, therefore the latter was
transfected with the chimeric HHDII construct to be
compatible with HHDII/DR1 mice. In addition, as both K562
and KCL-22 cells do not express HAGE, they were transduced
with the HAGE construct. All cell lines expressed WT1. TCC-S
cells were the only cells found to express HAGE, WT1 and HLA-
A2. Some of these cells were transfected with shRNA for WT1 to
produce TCC-S-HAGE+/WT1Low cells. Splenocytes derived
from HAGE/WT1-ImmunoBody® vaccinated animals were
stimulated once in vitro. These splenocytes were able to
recognise and kill targets in an antigen dependant manner.
Interestingly, although the number of IFN-g producing cells
generated with either vaccine alone was similar to those
generated when both were used simultaneously, the combined
vaccine led to a significant increase in cell killing compared to
either vaccines alone. Importantly, the level of HAGE protein
detected in the transduced cell lines was similar to that of the
naturally HAGE expressing TCC-S cells.Frontiers in Oncology | www.frontiersin.org 14In the absence of an available murine CML model that can be
used in the HLA transgenic mice we tested the efficacy of this
combination in in vivo tumour challenge experiments, wherein a
pre-defined dose of the modified hB16/HAGE
+/Luc+ cells, which
also endogenously express WT1, was injected subcutaneously as
a “Proof-of-Concept” to form tumour. The combination
vaccines were assessed in prophylactic and therapeutic trial.
This melanoma-derived tumour model is obviously far from
ideal being a solid tumour with a very different tumour
microenvironment to that of a blood-derived cancer. Therefore
one should be careful in translating the findings obtained here to
leukaemia. Nonetheless, results showed that the combination of
HAGE- and WT1-ImmunoBody® was able to significantly delay
tumour growth and prolong mouse survival when compared to
mice in the control group. Indeed, mice that did not receive the
vaccines exhibited faster growing tumours than those that
received the vaccines and had to be sacrificed earlier due to the
endpoint tumour size being reached. Interestingly, while the vast
majority of mice in the prophylactic group developed a slow
growing tumour, a distinct group of four mice exhibited faster
tumour growth and these had to be culled earlier than the
remaining six mice. Having seen such pattern of tumour
development detected by bioluminescent imaging, it would be
important, in the future, to continue administering the vaccines
to the animals showing such a trend before the tumour size
becomes too big. The mice in the therapeutic group exhibited a
reduction in tumour size while the immunisation regime was
ongoing, but as soon as the last injection of the vaccine was
performed, the tumour started to grow, highlighting the fine
balance between the efficacy of the vaccine and the increasing
immunosuppression of the microenvironment as described by
Schreiber’s group (39).
Comparing the outcomes of the present study with our
previous studies using either HAGE- or WT1-ImmunoBody®
vaccination programme as a monotherapy (data not shown), the
combined HAGE/WT1 ImmunoBody® vaccines used herein
were found to further improve the delay in the tumour growth
in pre-immunised mice, but also and importantly, to delay
tumour growth in a significant proportion of mice even when
the vaccines were used after tumour implantation. Significance
was not achieved when either vaccine was used on their own.
These observations highlight the importance of incorporating
epitopes from both HAGE and WT1 epitopes in future
immunotherapy strategies. Moreover, this novel combination
was found to induce notable HAGE- and WT1-specific T cells in
the tumour bearing mice which were culled later in the
experiment. This was in comparison to the mice that were
euthanised early in the study in order to assess the IFN-g
ELISpot assay on splenocytes derived from the immunised
mice so examination could occur before too much
immunosuppression could interfere with the results.
Immunophenotypic analysis on TILs and splenocytes isolated
from mice from different groups using flow cytometry
demonstrated a clear reverse in the CD4+/CD8+ ratio of TILs
in comparison with those derived from the spleens. Whereas theJune 2021 | Volume 11 | Article 636977
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than 75% of them were CD8+ T cells in the tumours. The high
percent of recruited CD8+ cells were found in both vaccinated
and non-vaccinated mice, thereby indicating that B16 tumour
cells were being recognised as non-self probably due to the
presence of HAGE and the luciferase reporter gene; the latter
has been reported to induce immunogenicity in mice tumours
(40, 41). However, the frequency of CD8+ TILs isolated from
mice that were vaccinated with combined vaccines in the
prophylactic and the therapeutic settings was significantly
higher than those derived from the control group, indicating
that these cells were the principal T cell type involved in
controlling tumour growth.
We also noted that the CD4+ and CD8+ TILs that trafficked
through the hB16/HAGE
+/Luc+ tumour model exhibited a
remarkable upregulation of PD-1 that was independent of the
immunisations. PD-1 expression is promptly induced on T cell
after TCR activation (42), and this expression is temporary, and
declines when immunogen is cleared. PD-1 is, however,
maintained and becomes persistently expressed on antigen-
specific T cells in cancer or chronic disease (43) leading to
functional impairment of CD8+ T-cells (44). As B16 expresses
PD-L1 (PD-1 ligand), it is possible that the PD-1/PD-L1 pathway
was activated and that this could be attributed to the modest
efficacy noticed in the therapeutic setting. However, the
prophylactic setting demonstrated significant benefits in terms
of prolonged mouse survival and resistance to tumour growth,
despite the upregulation of PD-1 on TILs. This suggests the
occurrence of other mechanisms that could enable the combined
vaccines in the prophylactic treatment to overcome PD-1/PD-L1
pathway activity. Because of the modest response seen in the
therapeutic setting, we would recommend the incorporation of
anti-PD-1/anti-PD-L1 in combination with novel vaccines to
study whether a further enhancement of the anti-tumour effect
that could be obtained.CONCLUSIONS
The present study revealed that the combined HAGE and WT1
vaccine was more effective than either vaccine alone,
demonstrating the superiority of combination HAGE- and
WT1- ImmunoBody® vaccines. CTLs generated using this
combination were also shown to specifically recognise and kill
relevant targets.
The WT1 sequence used in this study was completely human
and differs from the murine WT1 by a single amino-acid.
Although this had no consequence when used in double
transgenic mice, the same vaccine failed to generate any
detectable immune responses in syngeneic C57BL/6 mice
(Joshua Pearson, personal communication).
Although the observed delayed growth of the implanted
tumour cells was only significant in the prophylactic study,
these results also showed that the mice would have benefitted
from a more sustained vaccination strategy. Moreover, the fact
that B16 cells are PD-L1 positive and that CD3+ T cells were alsoFrontiers in Oncology | www.frontiersin.org 15positive for PD-1, means that one should consider continued
vaccinations post-tumour implantation, as well as consider the
inclusion of anti-PD-1 antibody therapy.
Overall, the data presented herein support the development of
vaccine strategies based on a combination of both HAGE- and
WT1-ImmunoBody® vaccines which could be further improved
with the use of immune checkpoint inhibitors.DATA AVAILABILITY STATEMENT
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Supplementary Figure 1 | HAGE and WT1 expression in CML stem cells and
normal stem cells. CML single cell (SC) gene expression data was downloaded from
GEO database (Acc. No. GSE76312, Giustacchini et al 2017), All data from single
cell CML cell line were removed from the matrix prior to the analysis. Single cell geneJune 2021 | Volume 11 | Article 636977
Almshayakhchi et al. HAGE/WT1 ImmunoBody Vaccines Against Leukaemiaexpression data was available for 1964 patient derived CML cells and 232 Normal
Hematopoietic cells (HSC). Gene expression values (RPKM) of CD34, CD38, HAGE
and WT1 genes were extracted from the data matrix and matched up with the
patient identities and clinical information. Values greater than 1RPKM were
considered as a positive expression. Both HAGE and WT1 expression on single
cells was shown to vary within patients with some cells express very high level of
HAGE while others do not. No expression was detected in HSC cells for both WT1
and HAGE expression highlightinh their tumour cell specific expression.Frontiers in Oncology | www.frontiersin.org 16Supplementary Figure 2 | Sequential, real-time in vivo analysis of tumour burden
in live animals assessed by Perkin Elmer IVIS Lumina III system. The figure reflects
intra-tumoral luciferin bioluminescence signals in anesthetised HHDII/DR1 mice
bearing hB16/HAGE
+/Luc+ tumour. Images from different groups point out a decline
in tumour size and prolonged mice survival in vaccinated group in comparison with
control. Colours overlying mice represent the rate of photons emission of the
luciferin per second, wherein, red refers to the highest photons density and violet
corresponding to the least detectable emission.REFERENCES
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